311 related articles for article (PubMed ID: 15005622)
1. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
[TBL] [Abstract][Full Text] [Related]
2. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies.
Barkhordarian H; Emadi S; Schulz P; Sierks MR
Protein Eng Des Sel; 2006 Nov; 19(11):497-502. PubMed ID: 16984950
[TBL] [Abstract][Full Text] [Related]
3. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
4. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
Emadi S; Barkhordarian H; Wang MS; Schulz P; Sierks MR
J Mol Biol; 2007 May; 368(4):1132-44. PubMed ID: 17391701
[TBL] [Abstract][Full Text] [Related]
5. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
6. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity.
Liu R; Yuan B; Emadi S; Zameer A; Schulz P; McAllister C; Lyubchenko Y; Goud G; Sierks MR
Biochemistry; 2004 Jun; 43(22):6959-67. PubMed ID: 15170333
[TBL] [Abstract][Full Text] [Related]
7. Characterizing antibody specificity to different protein morphologies by AFM.
Wang MS; Zameer A; Emadi S; Sierks MR
Langmuir; 2009 Jan; 25(2):912-8. PubMed ID: 19090748
[TBL] [Abstract][Full Text] [Related]
8. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein.
Zhou C; Emadi S; Sierks MR; Messer A
Mol Ther; 2004 Dec; 10(6):1023-31. PubMed ID: 15564134
[TBL] [Abstract][Full Text] [Related]
9. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
10. Effects of nitration on the structure and aggregation of alpha-synuclein.
Uversky VN; Yamin G; Munishkina LA; Karymov MA; Millett IS; Doniach S; Lyubchenko YL; Fink AL
Brain Res Mol Brain Res; 2005 Mar; 134(1):84-102. PubMed ID: 15790533
[TBL] [Abstract][Full Text] [Related]
11. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
[TBL] [Abstract][Full Text] [Related]
12. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
J Mol Biol; 2004 Jun; 340(1):127-39. PubMed ID: 15184027
[TBL] [Abstract][Full Text] [Related]
13. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
El-Agnaf OM; Irvine GB
J Struct Biol; 2000 Jun; 130(2-3):300-9. PubMed ID: 10940234
[TBL] [Abstract][Full Text] [Related]
14. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ; Lansbury PT
Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
[TBL] [Abstract][Full Text] [Related]
15. Identification of human alpha-synuclein specific single chain antibodies.
Maguire-Zeiss KA; Wang CI; Yehling E; Sullivan MA; Short DW; Su X; Gouzer G; Henricksen LA; Wuertzer CA; Federoff HJ
Biochem Biophys Res Commun; 2006 Nov; 349(4):1198-205. PubMed ID: 16973126
[TBL] [Abstract][Full Text] [Related]
16. Structural evidence for alpha-synuclein fibrils using in situ atomic force microscopy.
Zhang F; Ji LN; Tang L; Hu J; Hu HY; Xu HJ; He JH
Acta Biochim Biophys Sin (Shanghai); 2005 Feb; 37(2):113-8. PubMed ID: 15685368
[TBL] [Abstract][Full Text] [Related]
17. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
Fujiwara H; Hasegawa M; Dohmae N; Kawashima A; Masliah E; Goldberg MS; Shen J; Takio K; Iwatsubo T
Nat Cell Biol; 2002 Feb; 4(2):160-4. PubMed ID: 11813001
[TBL] [Abstract][Full Text] [Related]
18. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
Hoyer W; Cherny D; Subramaniam V; Jovin TM
Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
[TBL] [Abstract][Full Text] [Related]
19. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation.
Fernández CO; Hoyer W; Zweckstetter M; Jares-Erijman EA; Subramaniam V; Griesinger C; Jovin TM
EMBO J; 2004 May; 23(10):2039-46. PubMed ID: 15103328
[TBL] [Abstract][Full Text] [Related]
20. Forcing nonamyloidogenic beta-synuclein to fibrillate.
Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
